Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Adverum Biotechnologies is a clinical-stage biopharmaceutical company focused on developing gene therapies for prevalent ocular diseases, primarily wet age-related macular degeneration (wet AMD). Its lead product, Ixo-vec, is a single intravitreal injection gene therapy designed to provide sustained delivery of aflibercept, reducing treatment burden and improving vision outcomes. Adverum leverages proprietary AAV vector technology, scalable manufacturing, and clinical expertise to address unmet needs in ophthalmology.
This description was generated via AI from an annual report. Updated about 1 year ago.